TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00867334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib mesylate and panitumumab
Description: Patients will be entered into sequential cohorts with escalating doses of imatinib mesylate. After approximately 28 days of monotherapy treatment with imatinib mesylate, patients will be asked to have a liver biopsy performed (this biopsy is voluntary and is not required for continued participation in the study). All patients in this group will then receive imatinib mesylate in combination with standard-of-care doses of panitumumab. After approximately 1-2 months of combination treatment, patients will asked to have an additional liver biopsy performed (this biopsy is voluntary and is not required for continued participation in the study). Combination treatment will continue for the remainder of the subject's time in the trial.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard-of-care treatment with panitumumab
Description: Panitumumab as standard of care. After approximately 2-3 months of standard of care treatment, patients will asked to have a liver biopsy performed (this biopsy is voluntary and is not required for continued participation in the study).
Study: NCT02935036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADPS topical product
Description: topical product

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control
Description: topical product
Study: NCT04138355

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy
Description: ESWT was conducted using the Duolith SD-1® device (StorzMedical, Tägerwilen,Switzerland) with an electromagnetic cylindrical coil source for the focused shock wave. ESWT was performed around the primary treatment site at 100 impulses/cm2, an energy flux density(EFD) of 0.05 to 0.30 mJ/mm2, frequency of 4Hz, and 1000 to 2000 impulses were administered at 1-week intervals for 4 sessions.
Study: NCT01148771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ertapenem
Description: 1 gram IV bolus every 24 hours (q24h) for 3 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ertapenem
Description: 1 gram 30 minute infusion q24h for 3 days
Study: NCT03893357

Intervention type: OTHER
Intervention: Data extraction from medical files
Description: Retrospective data extraction from the medical files

Intervention type: OTHER
Intervention: Data extraction from medical files
Description: Retrospective data extraction from the medical files
Study: NCT01869673

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Face Mask
Description: Patients will be ventilated trough a face mask first and trough a oral mask thereafter

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oral Mask
Description: Patients will be ventilated trough an oral mask first and trough a face mask thereafter
Study: NCT03376386

Intervention type: RADIATION
Group type: OTHER
Intervention: Adaptive dose-Escalated multi-modality image-guided radiotherapy
Description: FDG-PET/CT-scan will be used twice during radiotherapy for a mild dose-escalation to the less-responding parts of the tumor. By adapting the radiotherapy plan, these areas will receive 74-78 Gy.
Study: NCT01995110

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high-fat meal B

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high-fat meal C

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high-fat meal C
Study: NCT01203631

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC 0142-0000-0002
Description: A single dose administered subcutaneously (s.c., under the skin)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single dose administered subcutaneously (s.c., under the skin)
Study: NCT02966769

Intervention type: OTHER
Intervention: Overall survival
Description: Compare overall survival between both groups.

Intervention type: OTHER
Intervention: Overall survival
Description: Compare overall survival between both groups.
Study: NCT00542360

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Marketing program to motivate exercise class participation
Description: Using qualitative research methods, a targeted social marketing program, including a 'marketing toolkit,' was developed to motivate participation in exercise classes by older adult members of churches. The Health Belief and Transtheoretical Models formed the theoretical basis for the social marketing planning process and guided program design. The marketing program aimed to increase exercise class attractiveness, usability, and uptake by reducing barriers and costs, and using messaging about benefits and enhanced convenience to motivate participation. The intervention was implemented through churches.
Study: NCT01950676

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smart phone application
Description: The smart phone application (Diabetes Pal), will guide patients on self-titration of insulin. Patients will be required to key in the CBG readings into the application. Up-titration of insulin dose will be carried out once every 3 days and the recommended insulin dose will be based on the mean of 3 CBG readings and a pre-specified titration algorithm. The process of using the insulin self-titration application will continue until the patient has reached the target pre-breakfast CBG.
Study: NCT04040205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Abemaciclib 200 mg will be taken by mouth twice daily.
Study: NCT03191279

Intervention type: PROCEDURE
Intervention: First aid
Description: Open airway (head tilt, chin lift), recovery position, staunch of bleeding, prevention of hypothermia, cooling of burn, CPR
Study: NCT02965664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PresbiDrops (CSF-1)
Description: PresbiDrops (CSF-1) is a topical ophthalmic drug.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo drops contain the same ingredients as PresbiDrops except for the active ingredients
Study: NCT02502331

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Test Oral Cholera Vaccine
Description: Thimerosal free, manufactured at 600 L scale killed bivalent (O1 and O139) whole cell-oral cholera vaccine (WC-OCV) manufactured by Eubiologics Co., Ltd.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Euvichol®
Description: Licensed, manufactured at 100 L scale killed bivalent (O1 and O139) whole cell-oral cholera vaccine (WC-OCV) manufactured by Eubiologics Co., Ltd.
Study: NCT04412434

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Electroencephalography (EEG)
Description: Electroencephalography (EEG) is a painless and harmless method to record the bioelectric activity of the brain. Clinically, EEG refers to the recording of the brain's spontaneous electrical activity over a period of time, as recorded from multiple electrodes placed on the scalp This method can be helpful in the diagnosis of many various brain diseases and pathological conditions.~For the examination, electrodes are placed on the head, using a special harmless gel, similar to gel, used in ultrasonographic studies.
Study: NCT04209192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosfomycin Tromethamine 3G Sachet
Description: Is the prophylactic drug which will be used in the intervention group.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amikacin
Description: Is the prophylactic drug which will be used in the control group.
Study: NCT02823847

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Screening Interview
Description: Participants asked about demographic information, and questions about history of tobacco, alcohol, and mouthwash use. Interview lasts about 7 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Carbon Monoxide Test
Description: Carbon monoxide testing given to participants at baseline. Participants blow into a device that measures the amount of carbon monoxide in the lungs.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Help Materials
Description: Participants who want to stop smoking are given referral information for a tobacco cessation program at baseline.~Participants with premalignant and malignant oral lesions \[PMOL\]) given printed materials and web-based programs for tobacco and alcohol cessation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Visual Oral Screening Examination
Description: Intraoral exam performed under incandescent (white light) conditions at baseline, and again two weeks later.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Direct Fluorescent Oral Visualization Examination
Description: Intraoral exam performed under reduced room lighting with a handheld autofluorescence imaging device at baseline, and again two weeks later.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oral Biopsy
Description: Premalignant and malignant oral lesions \[PMOL\]) still present 2 weeks after oral exam are biopsied.
Study: NCT00668096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levitra (Vardenafil, BAY38-9456)
Description: Vardenafil 5 mg or 10 mg or 20 mg, orally1 hour prior to sexual activity
Study: NCT03852433

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon Alfa-2a (PEG-IFN alfa)
Description: Administered via subcutaneous injections
Study: NCT06234280

Intervention type: DEVICE
Intervention: Implantation of Eluvia stent
Description: Implantation of Eluvia stent
Study: NCT02733250

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Pembrolizumab
Description: 200mg IV Day 1 of each 21 cycles

Intervention type: DRUG
Group type: OTHER
Intervention: Nab-Paclitaxel
Description: 100mg/m2 IV Day 1, 8 and 15 of every 21 day cycles
Study: NCT00570869

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CPR Anytime
Description: These participants will be consented, surveyed, asked to watch a 22-minute instructional Infant CPR DVD with an infant manikin.
Study: NCT04243213

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vibration Plate
Description: Vibration at 15° tilt, which means the patients partly use their own body weight (resistive vibration exercise).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tilt at 15°
Description: To compare if a possible effect derives from the vibration or the tilting only, a second group was added who will only receive 10 min of 15° tilt without the vibration.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tilt at 15°
Description: To compare if a possible effect derives from the vibration or the tilting only, a second group was added who will only receive 10 min of 15° tilt without the vibration.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard hospital mobilization
Description: early mobilization of patients 24h post surgery, done routinely, and physiotherapy this is done routinely in all patients

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard hospital mobilization
Description: early mobilization of patients 24h post surgery, done routinely, and physiotherapy this is done routinely in all patients

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard hospital mobilization
Description: early mobilization of patients 24h post surgery, done routinely, and physiotherapy this is done routinely in all patients
Study: NCT02528591

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: oscillometric device (Arteriograph®, Medexpert)
Description: Central blood pressure recorded in the non-fistula arm using a validated oscillometric device (Arteriograph®, Medexpert).
Study: NCT00668096

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo
Study: NCT02244073

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human insulin - Insulin administration to control blood glucose level.
Description: On ICU admission, the glycated hemoglobin level (A1c) is measured and insulin IV is possibly administered using a web based nurse driven insulin infusion protocol (https://extranet.chu-lyon.fr/cpg) to maintain blood glucose level below 10 mmol/l. Glycated hemoglobin result triggers patient randomization. Thereafter, during ICU stay, blood glucose level is maintained either below 1.59 × A1c - 1.59 (mmol/l) (Individualized blood glucose target group), or bellow 10 mmol/l (Conventional blood glucose target group).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human insulin - Insulin administration to control blood glucose level.
Description: On ICU admission, the glycated hemoglobin level (A1c) is measured and insulin IV is possibly administered using a web based nurse driven insulin infusion protocol (https://extranet.chu-lyon.fr/cpg) to maintain blood glucose level below 10 mmol/l. Glycated hemoglobin result triggers patient randomization. Thereafter, during ICU stay, blood glucose level is maintained either below 1.59 × A1c - 1.59 (mmol/l) (Individualized blood glucose target group), or bellow 10 mmol/l (Conventional blood glucose target group).
Study: NCT00857818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Aripiprazole administered orally as tablets, 5 mg once daily (QD) in Week 1; 10 mg QD in Week 2. Flexible dosing allowed after Week 2, adjusted in 5-mg increments every 7 days within a range of 10 to 30 mg daily, for 16 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oanzapine, risperidone, or quetiapine
Description: Oanzapine, risperidone, or quetiapine administered orally as tablets at prior dosage for 16 weeks
Study: NCT00949195

Intervention type: OTHER
Intervention: Measure pulmonary artery pressure change during exercise
Description: Semi-supine echocardiography test

Intervention type: OTHER
Intervention: Measure pulmonary artery pressure change during exercise
Description: Semi-supine echocardiography test

Intervention type: OTHER
Intervention: Pulmonary pressure response during exercise
Description: Semi-supine echocardiography test
Study: NCT05208424

Intervention type: DIAGNOSTIC_TEST
Intervention: Coronary angiography
Description: Invasive coronary angiography

Intervention type: DIAGNOSTIC_TEST
Intervention: Coronary angiography
Description: Invasive coronary angiography

Intervention type: DIAGNOSTIC_TEST
Intervention: Coronary angiography
Description: Invasive coronary angiography
Study: NCT01834924

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HELPix
Description: Low literacy, bilingual (English/Spanish) medication instruction sheets used as a framework for provider medication counseling, plus provider dose demonstration, parent teachback/showback, provider medication log review, provision of oral dosing syringe to parent
Study: NCT03572270

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: AMH test
Description: Blood test and pelvic ultrasound are performed at each visit to evaluate ovarian reserve

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: AMH test
Description: Blood test and pelvic ultrasound are performed at each visit to evaluate ovarian reserve

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: pelvic ultrasound
Description: Blood test and pelvic ultrasound are performed at each visit to evaluate ovarian reserve
Study: NCT03730350

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinical Hypnosis
Description: Hypnosis guidance and audio tracks aimed at promoting pain relief, reducing distress and anxiety, and facilitating sleep will be provided for independent use, with daily practice recommended. Each hypnosis session will be 20-25 minutes long. The scripts for these sessions have been developed based on the clinical literature (e.g., Elkins, 2014) and are already in use with patients of the pain service.
Study: NCT01264783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RNS60
Description: RNS60 for intravenous administration
Study: NCT02081703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AYX1 Injection 660 mg / 6 mL
Description: 6 mL solution for intrathecal injection with 660 mg of AYX1
Study: NCT03572270

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: pelvic ultrasound
Description: Blood test and pelvic ultrasound are performed at each visit to evaluate ovarian reserve
Study: NCT01615224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: misoprostol
Description: repeated doses of misoprostol. 400mcg of oral misoprostol given at 3, 5, 7 and 9 hours.
Study: NCT01596842

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 fatty acid ethylester 90
Description: Omega-3 fatty acid ethylester 90, Dosage form :1g soft capsule, Dosage : one capsule, thrice a day, Duration : 12 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Olive oil
Description: Olive oil, Dosage form :1g soft capsule, Dosage : one capsule, thrice a day, Duration : 12 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: cholecalciferol
Description: if baseline 25-hydroxyvitamin D levels are \< 15 ng/mL : 10,000IU/week, if baseline 25-hydroxyvitamin D levels are 16-30 ng/mL : 50,000IU/week, Duration : 12 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cholecalciferol
Description: if baseline 25-hydroxyvitamin D levels are \< 15 ng/mL : 10,000IU/week, if baseline 25-hydroxyvitamin D levels are 16-30 ng/mL : 50,000IU/week, Duration : 12 weeks
Study: NCT01387295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin, capecitabine, trastuzumab
Description: Oxaliplatin intrahepatic capecitabine and trastuzumab systemic
Study: NCT03392155

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training & Nutrition
Description: Exercise at moderate to high intensities and diet education/counseling
Study: NCT00816907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 500 mg to 1,000 mg taken twice daily for 16 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 to 2 placebo capsules taken twice daily for 16 weeks
Study: NCT01264783

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% normal saline for injection
Study: NCT02081703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AYX1 Injection 1100 mg / 10 mL
Description: 10 mL solution for intrathecal injection with 1100 mg of AYX1
Study: NCT01625598

Intervention type: PROCEDURE
Intervention: Photography of the retina
Description: Every subject will undergo photography of the retina in both eyes
Study: NCT02081703

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Injection 6 mL
Description: 6 mL solution for intrathecal injection; Vehicle formulation designed to mimic AYX1 Injection (with no active drug)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Injection 10 mL
Description: 10 mL solution for intrathecal injection; Vehicle formulation designed to mimic AYX1 Injection (with no active drug)
Study: NCT02878863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paeoniflorin + phosphatidylcholine or silymarin
Study: NCT01625598

Intervention type: PROCEDURE
Intervention: Retinal photography
Description: Device~Subjects will have photography of both eyes
Study: NCT01350349

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem Adaptation Therapy (PATH)
Description: Problem Adaptation Therapy (PATH) focuses on the subject, the caregiver, and the subject's home-environment, to encourage problem-solving and adaptive functioning. The goal of PATH is to decrease depression and disability.
Study: NCT02878863

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phosphatidylcholine or silymarin
Study: NCT00347269

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy
Description: Participants in CALM will choose to receive CBT, medication, or both for the treatment of their anxiety. CBT includes computer-assisted CBT with an anxiety clinical specialist.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psychotropic medication optimization
Description: For those participants in CALM who choose medication, the ACS will facilitate the delivery of, and adherence to, anti-anxiety medication which will be prescribed by the participants' PCP.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Participants in the control group will receive standard treatment from their PCP.
Study: NCT01013571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin glargine
Description: pre-filled disposable pen, in package of 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin glargine
Description: pre-filled disposable pen, in package of 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apidra (insulin glulisine)
Description: pre-filled disposable pen, in package of 5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apidra (insulin glulisine)
Description: pre-filled disposable pen, in package of 5
Study: NCT00849992

Intervention type: DRUG
Group type: OTHER
Intervention: Imiquimod 5%
Description: Imiquimod 5% cream used three days a week for 4 weeks

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Photodynamic therapy
Description: Photodynamic therapy involves applying Metvix cream to the affected area followed by illumination. It will be done twice during the study at a 2 week interval.
Study: NCT03032484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab is FDA approved as a treatment for recurrent Glioblastoma following failure of radiation therapy and temozolomide.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab is FDA approved as a treatment for recurrent Glioblastoma following failure of radiation therapy and temozolomide.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TVB-2640
Description: TVB-2640 is a potent and reversible inhibitor of the FASN enzyme. TVB-2640 inhibits the β-ketoacyl reductase (KR) enzymatic activity of the FASN enzyme.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TVB-2640
Description: TVB-2640 is a potent and reversible inhibitor of the FASN enzyme. TVB-2640 inhibits the β-ketoacyl reductase (KR) enzymatic activity of the FASN enzyme.
Study: NCT01350349

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Therapy
Description: Supportive Therapy assists subjects in expressing their feelings and focusing on their strengths and abilities in working through current difficulties and transitions.
Study: NCT03549169

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TOMAS
Description: Intervention focused on decision making for the management of symptoms aimed at adults with heart failure.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Regular attention
Description: Regular attention focused on education for therapeutic adherence